Brought to you by 
Roche in hostile takeover of next-gen sequencing company Illumina worth $5.5bn; withdrawn
23 Apr 2012
Executive Summary
Publicly traded Illumina Inc. (gene variation and function analysis) has received an unsolicited proposal to be acquired by Roche for $5.5bn, or $44.50 in cash per share, a 64% premium to the ten-day average prior to December 21, which is when rumors surfaced about a potential deal between the companies.
Deal Industry
- Research, Analytical Equipment & Supplies
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche in hostile takeover of next-gen sequencing company Illumina worth $5.5bn; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice